- Home
- TLSA vs ALEC Comparison
TLSA vs ALEC Comparison
Compare TLSA & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | ALEC |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.7M | 200.8M |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TLSA | ALEC |
|---|---|---|
| Price | $1.73 | $1.87 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 282.7K | ★ 1.2M |
| Earning Date | 05-06-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,048,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.26 |
| 52 Week Low | $0.63 | $0.87 |
| 52 Week High | $2.60 | $3.40 |
Technical Indicators
Market Signals| Indicator | TLSA | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 57.68 | 66.41 |
| Support Level | $1.32 | $1.74 |
| Resistance Level | $1.58 | $1.94 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 82.56 | 76.26 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.